DGAP-Media / 2020-02-07 / 11:03
*Aladdin Healthcare Technologies SE: Announces the appointment of Chief
Scientific Advisor David C. Rubinsztein*
*Professor Rubinsztein is a leader in the field of neurodegenerative disease
and autophagy.*
_BERLIN/LONDON, 07 February 2020 - _Aladdin Healthcare Technologies SE
_("Aladdin", ISIN: _DE000A12ULL2 [1]_), today announces that Professor David
C._ *Rubinsztein has been appointed as Chief Scientific Advisor. David is
the Deputy Director of the Cambridge University Institute of Medical
Research,* *Professor of Molecular Neurogenetics and Wellcome Trust
Principal Research Fellow. His research interests are in autophagy and
neurodegeneration.*
He is the Academic Lead of the Alzheimer's Research UK (ARUK) Cambridge Drug
Discovery Institute and a fellow of the Royal Society and the Academy of
Medical Sciences. David has received highly cited researcher rewards from
Clarivate Analytics and Thomson Reuters. He has been publishing more than
300 papers in well-known international journals including Nature and Cell,
with google citations of more than 75,000 times.
"I am delighted to welcome Professor David C. Rubinsztein as Chief
Scientific Advisor," said Wade Menpes-Smith, CEO of Aladdin Healthcare
Technologies SE. "As a leader within his industry, he will bring enormous
experience and expertise in the fields of neurodegenerative disease and
advise the product direction of our company. Moreover, David will help with
the validation process of the various prototypes on Aladdin's 'Early
Diagnosis Platform'. He will also lead the development of Aladdin's
neurodegenerative disease centric knowledge graph which aims to achieve
disease pathway discovery, target discovery and novel biomarker discovery.
*About Aladdin Healthcare Technologies SE*
Aladdin Healthcare Technologies SE (and its wholly owned subsidiary Aladdin
Healthcare Technologies Ltd.) is a leading developer of AI healthcare
diagnostics and drug discovery applications that can accelerate both early
stage disease diagnosis and the end-to-end drug discovery process. Aladdin
targets aged related disease including a significant focus on Alzheimer's
disease. Aladdin accomplishes this by collaborating with numerous partners
within the global healthcare ecosystem to confidentially and securely gather
targeted data including, genome, MRI, PET, cognition and other lifestyle
data. These datasets are then analysed by the award-winning AI team and used
to develop proprietary AI tools that can assist healthcare professionals to
more accurately and efficiently diagnose aged related diseases. This new
diagnostic process will save significant time and costs for healthcare
professionals. Additionally, the AI drug discovery platform will be used to
by pharmaceutical Companies to speed up drug development, clinical trials
and predict outcomes more accurately.
Website Link: www.aladdinid.com [2]
GSIN: A12ULL
ISIN: DE000A12ULL2 [1]
TICKER SYMBOL: NMI
*Contact Press*
CROSS ALLIANCE communication GmbH
Susan Hoffmeister
Phone +49 89 1250 90330
Email: sh@crossalliance.de
www.crossalliance.de [3]
End of Media Release
Issuer: Aladdin Healthcare Technologies SE
Key word(s): Health
2020-02-07 Dissemination of a Press Release, transmitted by DGAP - a service
of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
Language: English
Company: Aladdin Healthcare Technologies SE
Unter den Linden 10
10117 Berlin
Germany
Phone: 030 700140449
E-mail: info@aladdinid.com
Internet: www.aladdinid.com
ISIN: DE000A12ULL2
WKN: A12ULL
Listed: Regulated Market in Dusseldorf
EQS News ID: 970567
End of News DGAP Media
970567 2020-02-07
1: https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=ead13565eed11c61275a9f7fb2ee1f10&application_id=970567&site_id=vwd&application_name=news
2: https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=a2dd1bbc615be83abe8f7699163b31b0&application_id=970567&site_id=vwd&application_name=news
3: https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=2fb82c892c1fc6e111f3d23d87061155&application_id=970567&site_id=vwd&application_name=news
(END) Dow Jones Newswires
February 07, 2020 05:03 ET (10:03 GMT)
© 2020 Dow Jones News
